Unassociated Document
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): May 23, 2006
BODISEN
BIOTECH, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
333-99101
|
98-0381367
|
(State
or Other Jurisdiction
|
(Commission
File
|
(I.R.S.
Employer
|
of
Incorporation)
|
Number)
|
Identification
Number)
|
|
|
|
|
|
|
North
Part of Xinquia Road, Yang Ling Agricultural High-Tech
Industries
Demonstration Zone, Yang Ling,
People's
Republic of China 712100
(Address
of principal executive offices) (zip code)
86-29-87074957
(Registrant's
telephone number, including area code)
Copies
to:
Marc
J.
Ross, Esq.
Yoel
Goldfeder, Esq.
Sichenzia
Ross Friedman Ference LLP
1065
Avenue of the Americas
New
York,
New York 10018
Phone:
(212) 930-9700
Fax:
(212) 930-9725
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
7.01 Regulation FD Disclosure
On
Bodisen Biotech, Inc. expects to make a presentation concerning its business
to
potential business partners. The materials to be utilized during the
presentation is filed as Exhibit 99.1 to, and incorporated by reference in,
this
report. In accordance with Regulation FD, this current report is being filed
to
publicly disclose all information that was provided in its press release. This
report under Item 7.01 is not deemed an admission as to the materiality of
any
information in this report that is required to be disclosed solely by Regulation
FD.
Item
9.01 Financial Statements and Exhibits.
(a) |
Financial
statements of business acquired.
|
Not
applicable.
(b) |
Pro
forma financial information.
|
Not
applicable.
Exhibit
Number
|
|
Description
|
99.1
|
|
Presentation
Materials of Bodisen Biotech, Inc.
|
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
BODISEN
BIOTECH,
INC.
|
|
|
|
Date: May
23,
2006 |
By: |
/s/ Qiong
Wang |
|
Name:
Qiong
Wang |
|
Title:
Chief
Executive
Officer |